Ovulation
1
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
IBSA Institut BiochimiqueSwitzerland - Lugano-Pazzallo
1 programIbuprofenPHASE_2Small Molecule1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
TheramexVaginal micronized progesterone
IBSA Institut BiochimiqueIbuprofen
Oregon TherapeuticsCelebrex
Clinical Trials (3)
Total enrollment: 81 patients across 3 trials
Exogenous Progesterone as Ovulation Trigger
Start: Apr 2026Est. completion: Jun 202610 patients
Phase 4Not Yet Recruiting
Can Ibuprofen Delay Ovulation in Natural Cycle-IVF?
Start: Jan 2016Est. completion: Aug 202251 patients
Phase 2Completed
The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on Ovulation
Start: Sep 2009Est. completion: Sep 201120 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.